



US008268615B2

(12) **United States Patent**
Lanar et al.

(10) **Patent No.:** **US 8,268,615 B2**
(45) **Date of Patent:** **Sep. 18, 2012**

(54) **EXPRESSION, PURIFICATION AND USES OF A PLASMODIUM FALCIPARUM LIVER STAGE ANTIGEN 1 POLYPEPTIDE**

(75) Inventors: **David E. Lanar**, Takoma Park, MD (US); **Collette J. Hillier**, Concord (AU); **Jeffrey A. Lyon**, Accident, MD (US); **Evelina Angov**, Bethesda, MD (US); **Sanjai Kumar**, Gaithersburg, MD (US); **William Rogers**, FPO, AP (US); **Arnoldo Barbosa**, Tolima (CO)

(73) Assignee: **The United States of America as Represented by the Secretary of the Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 398 days.

(21) Appl. No.: **12/454,240**

(22) Filed: **May 14, 2009**

(65) **Prior Publication Data**
US 2010/0040640 A1 Feb. 18, 2010

Related U.S. Application Data

(62) Division of application No. 10/706,435, filed on Nov. 12, 2003, now Pat. No. 7,550,275.

(60) Provisional application No. 60/425,719, filed on Nov. 12, 2002.

(51) **Int. Cl.**
C12N 15/00 (2006.01)
A61K 39/002 (2006.01)

(52) **U.S. Cl.** **435/320.1**; 424/191.1

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,319,502 B1 11/2001 Guerin-Marchand et al.

OTHER PUBLICATIONS

Fidock et al., 1994. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J. Immunol. 153, 190-204.

Doolan et al., 2000. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453-1462.

Connelly et al., 1997. T-Cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect. Immunity 65, 5082-5087.

Krzych et al., 1995. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognized liver and blood stage malaria antigens. J. Immunol. 155, 4072-4077.

Druilhe et al., PLoS Medicine, 2, 11, 1135-1145, 2005.

Phillips, Clinical Microbiol. Rev., Jan. 2001, vol. 14, No. 1, pp. 208-226.

Giles, "Why don't we have a malaria vaccine?", <http://malaria.wellcome.ac.uk/doc>, Wellcome Trust malaria website, Feb. 17, 2007.

Londono et al., J. Immunol., vol. 145, pp. 1557-1563, Sep. 1, 1990.

Rodriguez, Ariane et al., 2008. Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1. Infection and Immunity 76, 1709-1718.

Primary Examiner — Nancy T Vogel

(74) *Attorney, Agent, or Firm* — Elizabeth Arwine

(57) **ABSTRACT**

In this application is described the expression and purification of a recombinant *Plasmodium falciparum* (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent.

15 Claims, 9 Drawing Sheets